Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
2007 1
2008 2
2009 1
2011 1
2014 1
2015 1
2016 2
2018 1
2019 1
2020 4
2021 5
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Updates for the treatment of EGPA.
Raffray L, Guillevin L. Raffray L, et al. Presse Med. 2020 Oct;49(3):104036. doi: 10.1016/j.lpm.2020.104036. Epub 2020 Jul 8. Presse Med. 2020. PMID: 32652104 Review.
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is the least frequent antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). ...
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is the least frequent antineutrophil cytoplasm …
Rituximab treatment of ANCA-associated vasculitis.
Raffray L, Guillevin L. Raffray L, et al. Expert Opin Biol Ther. 2020 Aug;20(8):899-910. doi: 10.1080/14712598.2020.1748597. Epub 2020 May 5. Expert Opin Biol Ther. 2020. PMID: 32293192 Review.
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). ...In addition, it remains to identify which patients will benefit the m …
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cyt …
[Churg-Strauss syndrome].
Lhote F. Lhote F. Presse Med. 2007 May;36(5 Pt 2):875-89. doi: 10.1016/j.lpm.2007.02.018. Epub 2007 Apr 3. Presse Med. 2007. PMID: 17408916 Review. French.
Its prevalence of 7 to 13 per million population makes it one of the rarest of the systemic vasculitides. Anti-MPO (antimyeloperoxidase) pANCA (ANCA with a perinuclear fluorescence pattern) is present in 35-40% of cases and appears to determine a subgroup of patients with …
Its prevalence of 7 to 13 per million population makes it one of the rarest of the systemic vasculitides. Anti-MPO (antimyeloperoxidase) pAN …
Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19.
Kartsonaki C, Baillie JK, Barrio NG, Baruch J, Beane A, Blumberg L, Bozza F, Broadley T, Burrell A, Carson G, Citarella BW, Dagens A, Dankwa EA, Donnelly CA, Dunning J, Elotmani L, Escher M, Farshait N, Goffard JC, Gonçalves BP, Hall M, Hashmi M, Sim Lim Heng B, Ho A, Jassat W, Pedrera Jiménez M, Laouenan C, Lissauer S, Martin-Loeches I, Mentré F, Merson L, Morton B, Munblit D, Nekliudov NA, Nichol AD, Singh Oinam BC, Ong D, Panda PK, Petrovic M, Pritchard MG, Ramakrishnan N, Ramos GV, Roger C, Sandulescu O, Semple MG, Sharma P, Sigfrid L, Somers EC, Streinu-Cercel A, Taccone F, Vecham PK, Kumar Tirupakuzhi Vijayaraghavan B, Wei J, Wils EJ, Ci Wong X, Horby P, Rojek A, Olliaro PL; ISARIC Clinical Characterisation Group. Kartsonaki C, et al. Int J Epidemiol. 2023 Apr 19;52(2):355-376. doi: 10.1093/ije/dyad012. Int J Epidemiol. 2023. PMID: 36850054 Free PMC article.
Microscopic polyangiitis: clinical aspects and treatment.
Lhote F, Cohen P, Généreau T, Gayraud M, Guillevin L. Lhote F, et al. Ann Med Interne (Paris). 1996;147(3):165-77. Ann Med Interne (Paris). 1996. PMID: 8796093 Review.
Renal insufficiency with creatininemia > 120 microns/l is present in the majority of patients. Antineutrophil cytoplasm antibodies (ANCA) are found in 75% of MPA patients and the majority of these ANCA detected are perinuclear-staining anti-myeloper …
Renal insufficiency with creatininemia > 120 microns/l is present in the majority of patients. Antineutrophil cytoplasm antibod …
Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis.
Kauffmann M, Bobot M, Robert T, Burtey S, Couvrat-Desvergnes G, Lavainne F, Puéchal X, Terrier B, Quéméneur T, Faguer S, Karras A, Brunet P, Couchoud C, Jourde-Chiche N; REIN registry and the French Vasculitis Study Group. Kauffmann M, et al. Clin J Am Soc Nephrol. 2021 Nov;16(11):1665-1675. doi: 10.2215/CJN.03190321. Clin J Am Soc Nephrol. 2021. PMID: 34750159 Free PMC article.
BACKGROUND AND OBJECTIVES: Kidney impairment of ANCA-associated vasculitides can lead to kidney failure. Patients with kidney failure may suffer from vasculitis relapses but are also at high risk of infections and cardiovascular events, which questions the maintenance of i …
BACKGROUND AND OBJECTIVES: Kidney impairment of ANCA-associated vasculitides can lead to kidney failure. Patients with kidney failure …
[Churg-Strauss syndrome].
Lhote F, Cohen P, Guilpain P, Guillevin L. Lhote F, et al. Rev Prat. 2008 Jun 15;58(11):1165-74. Rev Prat. 2008. PMID: 18689110 Review. French.
Its prevalence of 7 to 13 per million population makes it one of the rarest of the systemic vasculitides. Anti-MPO (antimyeloperoxydase) pANCA (ANCA with a perinuclear fluorescence pattern) are present in 35-40% of cases and appear to determine a subgroup of patients with …
Its prevalence of 7 to 13 per million population makes it one of the rarest of the systemic vasculitides. Anti-MPO (antimyeloperoxydase) pAN …
23 results